Genetic analysis of immunomodulating factors in sporadic Parkinson's disease

Journal of Neural Transmission

Volumn 107, Issue 5, 2000, Pages 553-562

  Kruger R ^a   Hardt, C ^a   Tschentscher, F ^a   Jackel S ^a   Kuhn, W ^a   Muller T ^a   Werner, J ^a   Woitalla, D ^a   Berg, D ^b   Kuhnl N ^c   Fuchs, G A ^c   Santos, E J M ^d   Przuntek, H ^a   Epplen, J T ^a   Schols L ^a   Riess, O ^e  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Parkinson Klinik Wolfach   (Germany)

^d FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^e Ruhr University Bochum ^*

Author keywords

Factor alpha; Genetics; Immunomodulation; Parkinson's disease; Tumor necrosis

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; HAPLOTYPE; HETEROZYGOSITY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0034116193     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070078     Document Type: Article

References (43)

1. Aggarwal BB, Natarajan K (1996) Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 7: 93-124
2. Barbeau A, Roy M, Bernier G, Campanella G, Paris S (1987) Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 14: 36-41
3. Benveniste EN, Tang LP, Law RM (1995) Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL6 and IL-10. Int J Dev Neurosci 613: 341-349
4. Bjugstad KB, Flitter WD, Garland WA, Su GC, Arendash GW (1998) Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res 795: 349-357
5. Blum-Degen D, Müller TH, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1-beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202: 17-20
6. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumor necrosis factor and it's receptors in Parkinson's disease. Neurosci Lett 172: 151-154
7. 2 receptor density. Mol Psychiatry 4: 213-215
8. Epplen C, Jackel S, Santos EJ, D'Souza M, Poehlau D, Dotzauer B, Sindern E, Haupts M, Rude KP, Weber F, Stover J, Poser S, Gehlen W, Malin JP, Przuntek H, Epplen JT (1997) Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 41: 341-52
9. Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, Lincoln S, Maraganore D, Adler C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J (1999) A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 8: 81-85
10. Fuchs P, Strehl S, Dworzak M, Himmler A, Ambros PF (1991) Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics 13: 219-224
11. Garnier-Gere P, Dillmann C (1992) A computer program for testing pairwise linkage disequilibria in subdivided populations. J Hered 83: 239
12. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD (1998) A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet 18: 262-265
13. Gruol DL, Nelson TE (1997) Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15: 307-339
14. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40: 445-452
15. Hannun YA, Obeid LM (1995) Ceramide an intracellular signal for apoptosis. Trends Biochem Sci 20: 73-77
16. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, Kobyashi T, Yokochi M, Wang M, Yoritaka Y, Kondo T, Kuzuhara S, Nakamura S, Shimizu N, Mizuno Y (1998) Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 44: 935-941
17. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355-363
18. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 94: 7531-7536
19. Jaeckel S, Epplen JT, Kauth M, Miterski B, Tschentscher F, Epplen C (1998) Polymerase chain reaction-single strand conformation polymorphism or how to detect reliably and efficiently each sequence variation in many samples and many genes. Electrophoresis 19: 3055-3061
20. Jönsson E, Sedvall G, Brene S, Gustavsson JP, Geijer T, Terenius L, Crocq MA, Lannfeld T, Tylec A, Sokoloff P, Schwartz JC, Wiesel FA (1996) Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry 40: 1032-1043
21. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608
22. Kolesnick R, Golde DW (1994) The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signalling. Cell 77: 325-328
23. Krüger R, Kuhn W, Müller Th, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet 18: 106-108
24. Krüger R, Vieira-Säcker AMM, Kuhn W, Schöls L, Przuntek H, Epplen JT, Riess O (1999) Analysis of the parkin deletion in sporadic and familial Parkinson's disease. J Neural Transm 106: 159-163
25. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659-2667
26. Mc Guire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D (1994) Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371: 508-511
27. McGeer EG, McGeer PL (1997) The role of the immune system in neurodegenerative disorders. Mov Disord 12: 855-858
28. Miyada CG, Klofelt C, Reyes AA, McLaughlin-Taylor E, Wallace RB (1985) Evidence that polymorphism in the murine major histocompatibility complex may be generated by the assortment of subgene sequeences. Proc Natl Acad Sci USA 82: 2890-2894
29. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-α (TNFα) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208-210
30. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211: 13-16
31. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, Rao ML, Heun R (1999) A genetic variation of the inflammatory cytokine interleukin 6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol 45: 666-668
32. Pollanen MS, Dickson DW, Bergeron C (1993) Pathology and biology of the Lewy Body. J Neuropathol Exp Neurol 52: 183-191
33. Polymeropoulos MH, Laavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, STenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
34. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific espression of tumor necrosis factor α. Proc Natl Acad Sci 92: 11294-11298
35. Raymond M, Rousset F (1995) Genepop (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 86: 248-249
36. Saitoh M, Nakamura S, Taga T, Hirano T, Kishimoto T, Kaziro Y (1988) Induction of neuronal differentiation in PC 12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol 8: 3546-3549
37. Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-345
38. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467-472
39. Svejgard A, Ryder LP (1982) HLA and disease - a survey. Immun Rev 70: 193-218
40. Svejgard A, Ryder LP (1994) HLA and disease associations; detecting the strongest association. Tissue Antigens 43: 18-27
41. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW (1994) Interleukin-6 (IL6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113-118
42. Tschentscher F (1998) Polymorphismen von Cytokinen (Interleukin-3, -6) und Multiple Sklerose. Thesis, Ruhr-University, Bochum
43. Wilson AG, Symons JA, McDowell TL, McDevitt HO (1997) Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci 94: 3195-3199